Mencord Plus

Olmesartan medoxomil and Hydrochlorothiazide, the active ingredients in Mencord Plus, are an angiotensin II receptor blocker and a thiazide diuretic presented as a tablet for oral administration. They are indicated for the management of high blood pressure in adult patients, helping to lower cardiovascular risk.

GNH USA supplies Mencord Plus as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics worldwide under strict quality‑assurance standards. The company supports global distribution with reliable logistics and regulatory expertise.

Mencord Plus, a combination antihypertensive, acts on the renin‑angiotensin system and promotes diuresis to control elevated blood pressure.

- Hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension, aiding long‑term cardiovascular risk management.

Mencord Plus may cause a range of adverse reactions. Patients should be aware of both frequent and rare events.

Common Side Effects: - Dizziness: transient light‑headedness, especially after the first doses. - Headache: mild to moderate intensity, often resolves with continued therapy. - Increased urination: due to the diuretic component, leading to more frequent bathroom visits. - Electrolyte imbalance: mild reductions in potassium or sodium levels. - Fatigue: general feeling of tiredness during early treatment.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing requiring immediate medical attention. - Acute kidney injury: sudden decline in renal function, particularly in patients with pre‑existing kidney disease. - Hyperkalemia: elevated blood potassium that can cause cardiac arrhythmias. - Severe hypotension: marked drop in blood pressure leading to fainting or shock. - Pancreatitis: rare inflammation of the pancreas presenting with abdominal pain and vomiting.

Before prescribing Mencord Plus, clinicians should consider several safety aspects. - Renal function monitoring: assess serum creatinine and eGFR periodically. - Electrolyte surveillance: check potassium and sodium levels, especially in patients on other diuretics. - Caution in the elderly: start at lower doses to reduce risk of orthostatic hypotension. - Avoid in severe hepatic impairment: drug metabolism may be altered. - Pregnancy and lactation: safety not established; use only if potential benefit outweighs risk. - Store at room temperature: keep in the original container, protect from moisture and light.

Mencord Plus can interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use may increase renal risk. - ACE inhibitors or other ARBs: may cause excessive potassium rise and renal dysfunction. - Lithium: risk of lithium toxicity due to reduced clearance. - NSAIDs: may blunt antihypertensive effect and impair renal function. - Other potassium‑sparing diuretics: increase risk of hyperkalemia.

Moderate Interactions (Monitor Closely): - Beta‑blockers: additive blood‑pressure lowering effect; monitor for hypotension. - Calcium channel blockers: may enhance antihypertensive response. - Warfarin: possible alteration of INR; check coagulation status. - Antidiabetic agents: diuretic may affect glucose control; monitor blood sugar. - Antimicrobials (e.g., ciprofloxacin): may increase serum levels of olmesartan.